# Barry Selick

> Harold E. “Barry” Selick is a scientist, company builder, investor and biotechnology executive whose career has repeatedly crossed the boundary between discovery and development. After early work on humanized antibody technology, leadership roles at Affymax and Camitro, nearly 15 years as Threshold Pharmaceuticals’ CEO, and five years leading commercialization at UCSF, he returned to an operating role in January 2023 as chief executive officer and director of Hinge Bio.

- **Role:** Chief Executive Officer and Director at Hinge Bio
- **Organizations:** Hinge Bio, Protagonist Therapeutics, University of California, San Francisco, Threshold Pharmaceuticals, Sofinnova Ventures, Camitro Corporation, Camitro UK, Affymax Research Institute, Protein Design Labs, Anergen, PDL BioPharma, Catalyst Biosciences, Amunix Pharmaceuticals
- **Education:** Bachelor of Arts in Biophysics, University of Pennsylvania, Doctor of Philosophy in Biology, University of Pennsylvania, Damon Runyon-Walter Winchell Cancer Fund Fellow and American Cancer Society Senior Fellow, University of California, San Francisco
- **Known for:** Co-invented technology underlying the creation of fully humanized antibody therapeutics while at Protein Design Labs., Applied the humanization technology to PDL’s first product, later developed and commercialized by Roche., Named a finalist for the European Patent Office’s 2014 Inventor of the Year Award for work on humanized antibodies.

## Career timeline

- **1980s** — Completed postdoctoral work at UCSF in Bruce Alberts’ laboratory, supported by Damon Runyon-Walter Winchell Cancer Fund and American Cancer Society fellowships.
- **Before 1992** — Held scientific positions at Anergen and Protein Design Labs; at PDL, co-invented technology underlying fully humanized antibody therapeutics.
- **1992-1999** — Worked at Affymax Research Institute, ultimately as vice president of research responsible for drug discovery and technology development.
- **1999-2002** — Co-founded and led Camitro Corporation and Camitro UK until their acquisition by ArQule.
- **2002-2007** — Served concurrently as a venture partner at Sofinnova Ventures.
- **2002-2017** — Led Threshold Pharmaceuticals as chief executive officer from Series A financing through its IPO and sale to Molecular Templates.
- **2017-2023** — Served as UCSF’s first vice chancellor for business development, innovation and partnerships before joining Hinge Bio in January 2023.
- **2023-present** — Chief executive officer and director of Hinge Bio.
- **2026** — Hinge Bio announced first-subject dosing in the Phase 1 trial of its lead program.

## Achievements

- Co-invented technology underlying the creation of fully humanized antibody therapeutics while at Protein Design Labs.
- Applied the humanization technology to PDL’s first product, later developed and commercialized by Roche.
- Named a finalist for the European Patent Office’s 2014 Inventor of the Year Award for work on humanized antibodies.
- Co-founded Camitro and led it through its acquisition by ArQule.
- Led Threshold Pharmaceuticals from its Series A financing through an initial public offering and its 2017 sale.
- Established UCSF’s InVent Fund to support the development of selected university discoveries before licensing or company formation.
- As Hinge Bio CEO, closed a $30 million Series A’ financing in January 2025 and led the company into first-in-human clinical development in 2026.

## Latest updates

- **2026-04** — Hinge Bio announced that the first subject had been dosed in the Phase 1 trial of its lead program, marking the company’s entry into first-in-human clinical development.
- **2025-10** — Hinge Bio announced FDA clearance of the investigational new drug application for its lead program.
- **2025-10** — Kyorin Pharmaceutical announced a Japan co-development and exclusive licensing agreement with Hinge Bio for the company’s lead program.
- **2025-09** — Hinge Bio expanded its clinical leadership team and announced publication of preclinical proof-of-concept data in Scientific Reports.
- **2025-01** — Hinge Bio closed a $30 million Series A’ financing led by Point72, with Ridgeback Capital, InVivium Capital and Lightswitch Capital participating.

## Links

- Website: https://hingebio.com
- LinkedIn: https://www.linkedin.com/in/barry-selick-741318263

---

Profile page: https://yespress.io/barry-selick
Published by YesPress — https://yespress.io
Last updated: 2026-08-18